BD is a leading global medical technology company that develops, manufactures, and sells medical devices, instrument systems, and reagents. The Company is dedicated to improving people's health throughout the world. BD is focused on improving drug delivery, enhancing the quality and speed of diagnosing infectious diseases and cancers, and advancing research, discovery and production of new drugs and vaccines. BD's capabilities are instrumental in combating many of the world's most pressing diseases. Founded in 1897 and headquartered in Franklin Lakes, New Jersey, BD employs approximately 29,000 associates in approximately 50 countries throughout the world. The Company serves health care institutions, life science researchers, clinical laboratories, the pharmaceutical industry, and the general public. For more information, please visit www.bd.com.
The BD Veritor™ Plus system provides objective, lab-quality immunoassay test results for healthcare providers and laboratorians in physician offices, clinics, hospitals and IDNs—within minutes. The system streamlines the point-of-care (POC) diagnostic workflow and allows providers to quickly review patient results and determine the appropriate treatment in a single consultation. It can also help detect infectious diseases such as influenza A and B, respiratory syncytial virus (RSV) and group A strep while the patient is still on site, which may facilitate decision making for earlier intervention.
The new wireless BD Veritor™ Plus System provides lab-quality immunoassay test results within minutes.
This fast and accurate solution streamlines the point-of-care (POC) diagnostic workflow and allows providers to quickly review patient results and determine the appropriate treatment in a single consultation. BD Veritor™ Plus System can help detect infectious diseases, such as influenza A and B, respiratory syncytial virus (RSV), and group A strep while the patient is still on site, which can enable faster decision-making for an earlier intervention opportunity.
Product Details and Ordering »
The first CLIA-waived flu A+B test referenced against PCR, a higher sensitivity standard than culture. Device is ready to insert into reader 10 minutes after same is added.